Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Pa… (NCT05308472) | Clinical Trial Compass
CompletedPhase 2
Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP
United States75 participantsStarted 2022-10-31
Plain-language summary
This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after completing the double-blind treatment period.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Aged 18 years or older at the time of signing the informed consent form (ICF).
✓. Diagnosis of EPP, based on medical history by ferrochelatase ( FECH) genotyping or by biochemical porphyrin analysis.
✓. Body weight ≥50 kg.
✓. Washout of at least 2 months prior to Screening of afamelanotide and dersimelagon, if applicable.
✓. Aspartate aminotransferase (AST) and alanine transaminase (ALT) \<2× upper limit of normal (ULN) and total bilirubin \<ULN (unless documented Gilbert syndrome) at Screening. Albumin \>lower limit of normal (LLN).
Exclusion criteria
✕. Major surgery within 8 weeks before Screening or incomplete recovery from any previous surgery.
✕. Other than EPP, an inherited or acquired red cell disease associated with anemia.
✕. A history or known allergic reaction to any investigational product excipients or history of anaphylaxis to any food or drug.
✕. History of liver transplantation.
✕. History of alcohol dependence or excessive alcohol consumption, as assessed by the Investigator.
✕. Human immunodeficiency virus (HIV), active Hepatitis B, or C.
✕. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study
What they're measuring
1
Percent Change From Baseline in Whole Blood Metal-free PPIX Levels
✕. Condition or concomitant medication that would confound the ability to interpret clinical, clinical laboratory, or participant diary data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.